PKC-3 promotes glioblastoma cell survival by phosphorylating and inhibiting BAD through a phosphatidylinositol 3-kinase pathway

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1813, Issue 6, 2011, Pages 1190-1197

  Desai, S ^a,b   Pillai, P ^a,b   Win Piazza, H ^a,b   Acevedo Duncan, M ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Bad; Cell survival; Glioma; PI (3) kinase; PKC

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAD; PROTEIN BCL XL; PROTEIN KINASE C IOTA; 2 MORPHOLINO 8 PHENYLCHROMONE; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; ANDROSTANE DERIVATIVE; BAD PROTEIN, HUMAN; CHROMONE DERIVATIVE; ENZYME INHIBITOR; ISOENZYME; MORPHOLINE DERIVATIVE; PROTEIN 14 3 3; PROTEIN BCL X; PROTEIN KINASE C; PROTEIN KINASE C LAMBDA; PROTEIN SERINE THREONINE KINASE; PYRUVATE DEHYDROGENASE (ACETYL TRANSFERRING) KINASE; PYRUVATE DEHYDROGENASE (ACETYL-TRANSFERRING) KINASE; SERINE; WORTMANNIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL SURVIVAL; ENZYME ACTIVITY; GLIOBLASTOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; BIOLOGICAL MODEL; CELL PROLIFERATION; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; GLIOMA; IMMUNOPRECIPITATION; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN MULTIMERIZATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR CELL LINE; WESTERN BLOTTING;

14-3-3 PROTEINS; ANDROSTADIENES; APOPTOSIS; BCL-ASSOCIATED DEATH PROTEIN; BCL-X PROTEIN; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHROMONES; ENZYME INHIBITORS; GLIOMA; HUMANS; IMMUNOPRECIPITATION; ISOENZYMES; MODELS, BIOLOGICAL; MORPHOLINES; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN KINASE C; PROTEIN MULTIMERIZATION; PROTEIN-SERINE-THREONINE KINASES; RNA INTERFERENCE; SERINE; SIGNAL TRANSDUCTION;

EID: 79955656029     PISSN: 01674889     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2011.03.007     Document Type: Article

References (42)

1. Parlato C., Barbarisi M., Moraci M., Moraci A. Surgery, radiotherapy and temozolomide in treating high-grade gliomas. Front. Biosci. 2006, 11:1280-1283.
2. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., Belanger K., Brandes A.A., Marosi C., Bogdahn U., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005, 352:987-996.
3. Couldwell W., Antel J.P., Apuzzo M.J.L., Yong V.W. Inhibition of growth of established human glioma cell lines by modulators of the protein kinase C system. J. Neurosurgery. 1990, 73:594-600.
4. Inoue M., Kishimoto A., Takai Y., Nishizuka Y. Studies on cyclic nucleotide-independent protein kinase and its proenzyme in mammalian tissues. II. Proenzyme and its activation by calcium-dependent protease from rat brain. J. Biol. Chem. 1977, 252:7610-7616.
5. Kishimoto A., Takai Y., Mori T., Kikkawa U., Nishizuka Y. Activation of calcium and phospholipid-dependent protein kinase by diacylglycerol, its possible relation to phosphotidylinositol turnover. J. Biol. Chem. 1980, 255:2273-2276.
6. Castagna M., Takai Y., Kaibuchi K., Sano K., Kikkawa U., Nishizuka Y. Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters. J. Biol. Chem. 1982, 257:7847-7851.
7. Hiroko Ohgaki Genetic pathways to glioblastomas. Neuropathology 2005, 25:1-7.
8. Kesari S., Ramakrishna N., Sauvageot C., Stiles C.D., Wen P.Y. Targeted molecular therapy of malignant gliomas. Curr. Neurol. Neurosci. Rep. 2005, 5:186-197.
9. Baldwin R.M., Parolin D.A.E., Lorimer I.A.J. Regulation of glioblastoma cell invasion by PKCι and RhoB. Oncogene 2008, 27:1-9.
10. Baldwin R.M., Barrett G.M., Parolin D.A.E., Gillies J.K., Paget J.A., Lavictoire S.J., Gray D.A., Lorimer I.A.J. Coordination of glioblastoma cell motility by PKCι. Mol. Cancer 2010, 9:233-245.
11. Akimoto K., Takahashi R., Moriya S., Nishioka N., Takayanagil J., Kimura K., Fukuil Y., Osada S., Mizuno K., Hirai S., Kazlauskas A., Ohno S. EGF or PDGF receptors activate atypical PKCι through phosphatidylinositol 3-kinase. EMBO J. 1996, 15:788-798.
12. Murray N.R., Fields A.P. Atypical protein kinase C iota protects human leukemia cells against drug induced apoptosis. J. Biol. Chem. 1997, 272:27521-27524.
13. Regala R.P., Weems C., Jamieson L., Copland J.A., Thomson E.A., Fields A.P. Atypical protein kinase Cι plays a role in human lung cancer cell growth and tumorigenicity. J. Biol. Chem. 2005, 180:31109-31115.
14. Baldwin R.M., Garette-Lalonde M., Parolin D.A.E., Krzyzanowski P.M., Andrade M.A., Lorimer I.A.J. Protection of glioblastoma cells from cisplatin cytotoxicity via protein kinase Cι-mediated attenuation of p38 MAP kinase signaling. Oncogene 2006, 25:2909-2919.
15. Regala R.P., Davis R.K., Kunz A., Khoor A., Leitges M., Fields A.P. Atypical protein kinase C iota is required for bronchioalveolar stem cell expansion and lung tumorigenesis. Cancer Res. 2009, 69:7603-7611.
16. Rodriguez E.M., Dunham E.E., Martin G.S. Atypical protein kinase C activity is required for extracellular matrix degradation and invasion by Src-transformed cells. J. Cell. Physiol. 2009, 22:171-182.
17. Takagawa R., Akimoto K., Ichikawa Y., Akiyama H., Kojima Y., Ishiguro H., Inayama Y., Aoki I., Kunisaki C., Endo I., Nagashima Y., Ohno S. High expression of atypical protein kinase C lambda/iota in gastric cancer as a prognostic factor for recurrence. Ann. Surg. Onco. 2010, 17:81-88.
18. Balendran A., Biondi R.M., Cheung P.C.F., Casamayor A., Deak M., Alessi D.R. A 3-phosphoinositide-dependent protein kinase-1 (PDK1) docking site is required for the phosphorylation of protein kinase Cι (PKCι) and PKC-related kinase 2 by PDK1. J. Biol. Chem. 2000, 275:20806-20813.
19. Regala R.P., Weems C., Jamieson L., Khoor A., Edell E.S., Lohse C.M., Fields A.P. Atypical protein kinase Cι is an oncogene in human non-small cell lung cancer. Cancer Res. 2005, 65:8905-8911.
20. Zhang L., Huang J., Yang N., Liang S., Barchetti A., Giannakakis A., Cadungog M.G., O'Brien-Jenkins A., Massobrio M., Roby K.F., et al. Integrative genomic analysis of protein kinase C (PKC) family identifies PKCiota as a biomarker and potential oncogene in ovarian carcinoma. Cancer Res. 2006, 66:4627-4635.
21. Chen-Levy Z., Nourse J., Cleary M.L. The bcl-2 candidate protooncogene product is a 24-kilodalton integral-membrane protein highly expressed in lymphoid cell lines and lymphomas carrying the t(14;18) translocation. Mol. Cell. Biol. 1989, 9:701-710.
22. Wei M., Zong W., Cheng E., Lindsten T., Panoutsakopoulou V., Ross A., Roth K., MacGregor G., Thompson C., Korsmeyer S. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 2001, 292:727-730.
23. Suzuki M., Youle R.J., Tjandra N. Structure of Bax coregulation of dimer formation and intracellular localization. Cell 2000, 103:645-654.
24. Kelekar A., Thompson C.B. Bcl-2-family proteins: the role of the BH3 domain in apoptosis. Trends Cell Biol. 1998, 8:324-330.
25. Petros A.M., Olejniczak E.T., Fesik S.W. Structural biology of the Bcl-2 family of proteins. Biochimi. Biophys. Acta. 2004, 1644:83-94.
26. Tan Y., Demeter M.R., Ruan H., Comb M.J. BAD Ser 155 phosphorylation regulates BAD/Bcl-XL Interaction and cell survival. J. Biol. Chem. 2005, 275:25865-25869.
27. Huang D.C., Strasser A. BH3-only proteins-essential initiators of apoptotic cell death. Cell 2000, 103:839-842.
28. Hirai I., Wang H.G. Survival-factor-induced phosphorylation of Bad results in its dissociation from Bcl-xL but not Bcl-2. Biochem. J. 2001, 359:345-352.
29. Datta S.R., Kaisov A., Hu L., Petros A., Fesik S.W., Yaffe M.B., Greenberg M.E. 14-3-3 Proteins and survival kinases cooperate to inactivate BAD by BH3 domain phosphorylation. Mol. Cell 2000, 6:41-51.
30. Juin P., Genesteb O., Raimbaudb E., Hickman J.A. Shooting at survivors: Bcl-2 family members as drug targets for cancer. Biochim. Biophys. Acta. 2004, 1644:251-260.
31. Strik H., Deininger M., Streffer J., Grote E., Wickboldt J., Dichgans J., Weller M., Meyermann R. BCL-2 family protein expression in initial and recurrent glioblastomas: modulation by radiochemotherapy. J. Neurol. Neurosurg. Psychiatry 1999, 67:763-768.
32. Patel R., Win H., Desai S., Patel K., Matthews J.A., Acevedo-Duncan M. Involvement of PKC-ι in glioma proliferation. Cell Prolif. 2008, 41:122-135.
33. Jin Z., Xin M., Deng X. Survival function of protein kinase Cι as a novel nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-activated Bad kinase. J. Biol. Chem. 2005, 280:16045-16052.
34. Ponten J., MacIntyre E.H. Long term culture of normal and neoplastic glia. Acta Pathol. Microbiol. Scand. 1968, 74:465-486.
35. Bradford M.M. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the property of protein-dye binding. Anal. Biochem. 1976, 72:248-254.
36. Win H.Y., Acevedo-Duncan M. Role of protein kinase C-iota in transformed non-malignant RWPE-1 cells and androgen-independent prostate carcinoma DU-145 cells. Cell Prolif. 2009, 42:182-194.
37. Davis J.S., Clark M.R. Activation of protein kinase in the bovine corpus luteum and Ca2+. Biochem. J. 1983, 214:569-574.
38. Win H.Y., Acevedo-Duncan M. Atypical protein kinase C phosphorylates IKKαβ in transformed non-malignant and malignant prostate cell survival. Cancer Lett. 2008, 270:302-311.
39. Collins B.J., Deak M., Murray-Tait V., Storey K.G., Alessi D.R. In vivo role of the phosphate groove of PDK1 defined by knockin mutation. J. Cell Sci. 2005, 118:5023-5034.
40. Danial N.N. BAD: undertaker by night, candyman by day. Oncogene 2009, 27:S53-S70.
41. Fernando R., Foster J.S., Bible A., Ström A., Pestell R.G., Rao M., Saxton A., Joon Baek S., Yamaguchi K., Donnell R., Cekanova M., Wimalasena J. Breast cancer cell proliferation is inhibited by BAD: regulation of cyclin D1. J. Biol. Chem. 2007, 282:28864-28873.
42. Scotti M.L., Bamlet W.R., Smyrk T.C., Fields A.P., Murray N.R. Protein kinase Cι is required for pancreatic cancer cell transformed growth and tumorigenesis. Cancer Res. 2010, 70:2064-2074.